期刊
LUNG CANCER
卷 111, 期 -, 页码 65-68出版社
ELSEVIER IRELAND LTD
DOI: 10.1016/j.lungcan.2017.07.012
关键词
NSCLC; Adenocarcinoma; EGFR; Small cell lung cancer; Transformation; Nivolumab
资金
- NHS
Small cell transformation is a rare but well recognised mechanism of acquired resistance to EGFR-TKI therapy in EGFR-mutated NSCLC, but optimal drug therapy thereof is unknown. Nivolumab has demonstrated activity in relapsed de novo small cell lung cancer in early phase trials. Here, we report a case of transformed EGFR-mutant SCLC treated with nivolumab with no benefit.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据